John Redmond
Psychiatric/Mental Health · Cordova, TNNPI 1417554361
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,475 of the $22,853 with a category attached, or 63.3%. Axsome Therapeutics, Inc. accounts for 72.4% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $19,481, more than ten times the $307 reported in 2021. Among psychiatric/mental health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 240 payments — averaging $95.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$17K
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neuronetics, Inc.$889
- AbbVie$486
- Takeda Pharmaceuticals U.S.A., Inc.$356
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$14,47563%
- Travel & lodging$2,66612%
- Food & beverage$5,65225%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 39 | $16,535 |
| Johnson & Johnson | 29 | $1,781 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $1,097 |
| Neuronetics, Inc. | 3 | $889 |
| AbbVie | 27 | $486 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $356 |
| Otsuka America Pharmaceutical, Inc. | 17 | $301 |
| Alkermes, Inc. | 11 | $281 |
| Supernus Pharmaceuticals, Inc. | 12 | $221 |
| Vanda Pharmaceuticals Inc. | 9 | $220 |
| Lundbeck LLC | 6 | $145 |
| Collegium Pharmaceutical, Inc. | 4 | $81 |
| E.r. Squibb & Sons, L.L.C. | 3 | $79 |
| Tris Pharma Inc | 4 | $70 |
| Corium, LLC | 4 | $65 |
| Neurocrine Biosciences, Inc. | 3 | $59 |
| Acadia Pharmaceuticals Inc | 2 | $46 |
| Ironshore Pharmaceuticals Inc. | 2 | $41 |
| Boston Scientific | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Indivior Inc. | 1 | $25 |
| Atricure, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$15,717
- SPRAVATO$1,167
- NEUROSTAR TMS THERAPY SYSTEM$889
- CAPLYTA$346
- VRAYLAR$110
How this compares
$22,853 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 12 | $20,620 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $16,960 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 20 | $1,174 |
| Bupropion XlBupropion Hcl | 27 | $1,056 |
| Escitalopram Oxalate | 14 | $180 |
| Hydroxyzine Pamoate | 13 | $156 |
| Mirtazapine | 11 | $135 |
| Sertraline Hcl | 24 | $130 |
| Topiramate | 13 | $107 |
| Gabapentin | 17 | $103 |
| Lamotrigine | 14 | $47 |
| Diazepam | 14 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,097 | $20,62012 claims |
| Alkermes, Inc.Lybalvi | $281 | $16,96011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Cordova
- Uthappa MukatiraCordova$44K
- Derrick MeadowCordova$34K
- Mark HesselrodeCordova$9K
- Amanda WoodallCordova$8K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
- Mary AllenMemphis$422K
- Lauren HansenNashville$263K
- Joshua ThompsonChattanooga$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.